sponsored
PatientsVille.com Logo

PatientsVille

Avelox Medical Research Studies

Up-to-date List of Avelox Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Avelox Medical Research Studies

Rank Status Study
1 Unknown  Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
Condition: Liver Abscess
Interventions: Drug: Moxifloxacin (Avelox);   Drug: ceftriaxone (Rocephin/Cefin)
Outcome Measures: Treatment efficacy;   Clinical response;   Clinical and radiological response;   All cause mortality;   Mortality attributable to liver abscess during treatment;   Rates of complication (metastatic infections to the central nervous system and/or eyes);   Rates of gastrointestinal colonization of Klebsiella pneumoniae in patients and rates of resistance post-antibiotic use.
2 Unknown  Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation
Condition: Eye Infection/Inflammation Other
Interventions: Drug: moxifloxacin 0,5% + prednisolone 1%;   Drug: moxifloxacin/prednisolone combination
Outcome Measures: Day 15 Evaluation of Anterior Chamber;   day 15 physician´s follow-up impression of inflammatory reaction score
3 Recruiting To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: Selumetinib;   Drug: Moxifloxacin;   Drug: selumetinib
Outcome Measures: Effect of a single dose of selumetinib (75 mg) on the change in time-matched QTcF interval compared to placebo.;   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time from time zero to infinity (AUC);   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-t);   Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent volume of distribution at equilibrium, mean residence time (MRT)*CL/F (Vss/F);   Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent systemic plasma clearance (CL/F);   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of apparent terminal phase of volume at distribution (selumetinib and moxifloxacin only) (Vz/F);   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal half-life (t1/2).;   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal rate constant (λz);   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of mean residence time (MRT);   Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of AUC metabolite to parent ratio, N-desmethyl selumetinib (MRAUC);   Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of Cmax metabolite to parent ratio, N-desmethyl selumetinib (MRCmax);   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of time to Cmax (tmax).;   Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of maximum plasma concentration (Cmax);   The effect of selumetinib on additional ECG variables (QT, HR, RR, QRS, PR) and QTcB;   The maximum of the mean changes in time-matched QTcF interval after moxifloxacin administration compared to placebo
4 Not yet recruiting Effect of Glucose on QTc Interval in Type 1 Diabetes
Condition: Diabetes
Interventions: Drug: Moxifloxacin;   Other: hyper-glycaemic clamp
Outcome Measures: ECG Analysis;   Pharmacokinetics;   Pharmacodynamic analysis
5 Not yet recruiting A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
Condition: Infections, Bacterial
Interventions: Drug: GSK1322322 1200 mg;   Drug: GSK1322322 3000 mg;   Drug: Placebo;   Drug: Moxifloxacin
Outcome Measures: Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) for GSK1322322 as compared with time-matched placebo;   Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), Individual (linear) QT correction (QTci), QT, and heart rate (HR);   Change from baseline in QTcB, QTci, QT, and HR;   Plasma concentrations and selected pharmacokinetic (PK) parameters of moxifloxacin;   Plasma concentrations and selected PK parameters of GSK1322322/moxifloxacin;   Safety and tolerability of GSK1322322 as assessed by change from baseline in 12-lead ECGs;   Safety and tolerability of GSK1322322 as assessed by change from baseline in vital signs;   Safety and tolerability of GSK1322322 as assessed by number of subjects with adverse events;   Safety and tolerability of GSK1322322 as assessed by change from baseline in toxicity grading of clinical laboratory tests
6 Recruiting Improving Retreatment Success (IMPRESS)
Condition: Recurrent Tuberculosis
Intervention: Drug: moxifloxacin
Outcome Measures: A moxifloxacin-containing regimen, substituting moxifloxacin for ethambutol, is superior to a control regimen in improving treatment outcomes;   1.Time to culture-conversion of the moxifloxacin regimen and the ethambutol regimen using data from 2-, 4-, 6-, and 8-week cultures;   Compare the proportion of patients with any Grade 3 or 4 adverse reactions;   Compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients;   Compare the rates of treatment failure and recurrence of the intervention and control arm.
7 Recruiting Moxifloxacin_QT Study in Chinese Healthy Volunteer
Condition: QT Interval Prolongation
Interventions: Drug: moxifloxacin;   Drug: moxifloxacin-placebo
Outcome Measures: baseline-adjusted, placebo-corrected effect on QTcF (ΔΔQTcF);   Heart rate, PR, QRS, QTcB and QTcI
8 Unknown  Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
Condition: Community Acquired Pneumonia
Interventions: Drug: Moxifloxacin;   Drug: Ampicillin;Amoxicillin
Outcome Measures: Proof of the clinical non inferiority by the cure rate at the treatment of a Pneumonia at the therapy end (round 3: Day 7 to 10) with a standard penicillin in a high dosage;   clinical cure rate;   bacteriological effectiveness on patients and seed level;   bacteriological sensitivity into-vitro;   time up to the drug-switch;   time until the dismissal of the patients necessity of the gift of additional antibacterial drug;   cost reduction of the antibiotic-therapy and the complete treatment;   assessment of the effectiveness by the investigator
9 Recruiting Treatment of Mycobacterium Xenopi Pulmonary Infection
Condition: Atypical; Mycobacterium, Pulmonary, Tuberculous
Interventions: Drug: Clarithromycin;   Drug: Moxifloxacin
Outcome Measures: Sputum conversion at 6 months under three antibiotics treatment (Rifampin, ethambutol and a third drug clarithromycin or moxifloxacin);   Sputum conversion at 3, 6, 9 and 12 months of treatment in the two different arms (clarithromycin containing regimen versus moxifloxacin containing regimen;   Clinical and radiological outcome after 3, 6 and 12 months of treatment according to the treatment arm;   Mortality after 12 months of treatment in the two compared regimen;   Gastrointestinal toxicity and hematotoxicity after 1- 3- 6- 9- 12- months of treatment
10 Not yet recruiting Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP
Condition: Cholangitis
Interventions: Drug: Moxifloxacin;   Drug: ceftriaxone
Outcome Measures: cholangitis;   30 day mortality
11 Unknown  Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
Condition: Primary Pterygium
Intervention: Drug: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
Outcome Measures: rate of corneal epithelial defect closure;   toxicity findings: punctate keratitis, inferior conjunctival hyperemia, conjunctival papillary reaction
12 Recruiting Pharmacokinetics of Moxifloxacin in Patients With Pneumonia
Condition: Pneumonia
Intervention:
Outcome Measure: The concentration of Moxifloxacin in blood-plasma
13 Unknown  Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: Abscess, Intra-Abdominal
Intervention: Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Outcome Measures: Clinical success / failure rate at the Test-of-Cure visit;   Clinical + Bacteriological response at End-of-Treatment-visit;   Time to discharge from hospital;   Course of disease on the basis of clinical and laboratory parameters;   safety and tolerability of the study medication;   cost effectiveness of treatment regimes
14 Recruiting Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers
Condition: Cardiac Toxicity
Intervention: Drug: Moxifloxacin
Outcome Measure: ΔΔQTcF
15 Not yet recruiting Genetics of QT Response to Moxifloxacin
Condition: Cardiac Arrhythmias
Interventions: Drug: Moxifloxacin 400mg once time;   Drug: Placebo
Outcome Measure: QT interval duration
16 Unknown  Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
Condition: Community-Acquired Pneumonia
Interventions: Drug: moxifloxacin;   Drug: levofloxacin;   Drug: metronidazole
Outcome Measure: Clinical response
17 Recruiting Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin;   Drug: Moxifloxacin
Outcome Measures: Early clinical response rate in the Intent to Treat (ITT) population;   Early clinical response rate in the microITT population;   Clinical success rates in the ITT and Clincally Evaluable (CE) populations
18 Recruiting Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin;   Drug: Moxifloxacin
Outcome Measures: Early clinical response rate in the Intent to Treat (ITT) population.;   Early clinical response rate in the microITT population;   Clinical success rates in the ITT and Clinically Evaluable (CE) populations
19 Unknown  Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
Conditions: Helicobacter Pylori Infection;   Chronic Gastritis
Interventions: Drug: esomeprazole;   Drug: moxifloxacin;   Drug: amoxicillin
Outcome Measures: Efficacy of a combination of esomeprazole (E), moxifloxacin (M) and amoxicillin (A) for third line therapy of H. pylori infection.;   Comparison of EMA 7 days versus EMA 14 days. Hypothesis: superiority of EMA 14 days 4 weeks after end of eradication therapy;   Tolerability,safety, post treatment resistance, influence of host genetics (CYP status) and pathogenicity factors of H. pylori on treatment success.
20 Unknown  Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
Condition: Intravitreal Injection Patients
Intervention: Drug: Vigamox
Outcome Measure: Timed study

These studies may lead to new treatments and are adding insight into Avelox etiology and treatment.

A major focus of Avelox research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Avelox